|
|
| (191 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC____NOTOC__
| | __NOTOC__ |
| {{Hyperparathyroidism}}
| |
|
| |
|
| {{CMG}}; {{AE}} {{Anmol}} | | {{CMG}}; {{AE}} {{Anmol}} |
|
| |
|
| == Classification == | | ==Tables== |
| {| class="wikitable" | | {| class="wikitable" |
| ! colspan="4" |Classification of hyperparathyridism | | |+ |
| | !Diagnosis |
| | !Lab findings |
| | ! |
| | ! |
| |- | | |- |
| |Features
| | ! |
| |'''Primary hyperparathyroidism'''
| | ! |
| |'''Secondary hyperparathyroidism'''
| | ! |
| |'''Tertiary hyperparathyroidism'''
| | ! |
| |- | | |- |
| |Pathology | | | |
| |Hyperfunction of parathyroid cells due to hyperplasia, adenoma or carcinoma. | | | |
| |Physiological stimulation of parathyroid in response to hypocalcaemia. | | | |
| |Following long term physiological stimulation leading to hyperplasia. | | | |
| |- | | |- |
| |Cause
| |
| | | | | |
| | | | | |
| | | | | |
| |-
| |
| |Associations
| |
| |May be associated with multiple endocrine neoplasia.
| |
| |Usually due to chronic renal failure or other causes of Vitamin D deficiency.
| |
| |Seen in chronic renal failure.
| |
| |-
| |
| |Serum calcium
| |
| |High
| |
| |Low/Normal
| |
| |High
| |
| |-
| |
| |Serum phosphate
| |
| |Low/Normal
| |
| |High
| |
| |High
| |
| |-
| |
| |Management
| |
| |Usually surgery if symptomatic. Cincacalcet can be considered in those not fit for surgery.
| |
| |Treatment of underlying cause.
| |
| |Usually cinacalcet or surgery in those that don't respond.
| |
| |}
| |
|
| |
| =Causes=
| |
| ==Overview==
| |
| Hyperparathyroidism is caused by an increase in concentration of parathyroid hormone in serum. There are three type of hyperparathyroidism including primary, secondary and tertiary hyperparathyroidism. The are an array of different causes for all types of hyperparathyroidism.
| |
|
| |
| ==Causes of Primary hyperparathyroidism==
| |
| Causes of primary hyperparathyroidism are as follows:
| |
| ===Common causes===
| |
| *Parathyroid adenoma
| |
| **Usually single gland affected
| |
| **Sometimes multiple gland affected
| |
|
| |
| ===Less common causes===
| |
| *Parathyroid hyperplasia
| |
| *Parathyroid carcinoma
| |
| *Familial isloated hyperparathyroidism
| |
| *Radiation exposure (due to development of parathyroid adenoma or parathyroid hyperplasia)<ref name="pmid21848480">{{cite journal| author=Boehm BO, Rosinger S, Belyi D, Dietrich JW| title=The parathyroid as a target for radiation damage. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 7 | pages= 676-8 | pmid=21848480 | doi=10.1056/NEJMc1104982 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21848480 }} </ref><ref name="pmid18774659">{{cite journal| author=McMullen T, Bodie G, Gill A, Ihre-Lundgren C, Shun A, Bergin M et al.| title=Hyperparathyroidism after irradiation for childhood malignancy. | journal=Int J Radiat Oncol Biol Phys | year= 2009 | volume= 73 | issue= 4 | pages= 1164-8 | pmid=18774659 | doi=10.1016/j.ijrobp.2008.06.1487 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18774659 }} </ref><ref name="pmid890665">{{cite journal| author=Tisell LE, Hansson G, Lindberg S, Ragnhult I| title=Hyperparathyroidism in persons treated with X-rays for tuberculous cervical adenitis. | journal=Cancer | year= 1977 | volume= 40 | issue= 2 | pages= 846-54 | pmid=890665 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=890665 }} </ref>
| |
| *Celiac disease<ref name="pmid17148709">{{cite journal |vauthors=Maida MJ, Praveen E, Crimmins SR, Swift GL |title=Coeliac disease and primary hyperparathyroidism: an association? |journal=Postgrad Med J |volume=82 |issue=974 |pages=833–5 |year=2006 |pmid=17148709 |pmc=2653933 |doi=10.1136/pgmj.2006.045500 |url=}}</ref><ref name="pmid22238405">{{cite journal |vauthors=Ludvigsson JF, Kämpe O, Lebwohl B, Green PH, Silverberg SJ, Ekbom A |title=Primary hyperparathyroidism and celiac disease: a population-based cohort study |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=3 |pages=897–904 |year=2012 |pmid=22238405 |pmc=3319223 |doi=10.1210/jc.2011-2639 |url=}}</ref>
| |
|
| |
| ===Genetic causes===
| |
| *HRPT2 gene mutations:<ref name="pmid14585940">{{cite journal| author=Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D et al.| title=Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 18 | pages= 1722-9 | pmid=14585940 | doi=10.1056/NEJMoa031237 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14585940 }} </ref>
| |
| **HRPT2 gene code for parafibromin protein.
| |
| **HRPT2 gene mutations are found in a type of familial hyperparathyroidism, hyperparathyroidism-jaw tumor (HPT-JT) syndrome.
| |
| **HRTP2 gene mutations increases risk of parathyroid carcinoma.
| |
| *Cyclin D1 gene (CCND1)/PRAD1 gene:<ref name="pmid19373510">{{cite journal| author=Westin G, Björklund P, Akerström G| title=Molecular genetics of parathyroid disease. | journal=World J Surg | year= 2009 | volume= 33 | issue= 11 | pages= 2224-33 | pmid=19373510 | doi=10.1007/s00268-009-0022-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19373510 }} </ref><ref name="pmid8626826">{{cite journal| author=Hsi ED, Zukerberg LR, Yang WI, Arnold A| title=Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 5 | pages= 1736-9 | pmid=8626826 | doi=10.1210/jcem.81.5.8626826 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8626826 }} </ref>
| |
| **PRAD1 (parathyroid adenoma 1) is a protooncogene located on chromosome 11q13.
| |
| **Cyclin D1 gene translocation and oncogene action observerd in 8% of adenomas
| |
| **Cyclin D1 gene overexpression is pbserved in 20% to 40% of parathyroid adenomas
| |
| *MEN1 gene:<ref name="pmid19373510">{{cite journal| author=Westin G, Björklund P, Akerström G| title=Molecular genetics of parathyroid disease. | journal=World J Surg | year= 2009 | volume= 33 | issue= 11 | pages= 2224-33 | pmid=19373510 | doi=10.1007/s00268-009-0022-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19373510 }} </ref><ref name="pmid9215689">{{cite journal| author=Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC et al.| title=Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. | journal=Hum Mol Genet | year= 1997 | volume= 6 | issue= 7 | pages= 1169-75 | pmid=9215689 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9215689 }} </ref>
| |
| **MEN1 is a tumor supressor gene on chronosome 11q13.
| |
| **Somatic loss of single MEN1 allele is observed in 25% to 40% of sporadic parathyroid adenomas.
| |
|
| |
| ==Causes of secondary hyperparathyroidism==
| |
| Causes of secondary hyperparathyroidism are as follows:
| |
| ===Common causes===
| |
| *Chronic renal failure (leading to parathyroid hyperplasia)<ref name="pmid15507543">{{cite journal| author=Rodriguez M, Nemeth E, Martin D| title=The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. | journal=Am J Physiol Renal Physiol | year= 2005 | volume= 288 | issue= 2 | pages= F253-64 | pmid=15507543 | doi=10.1152/ajprenal.00302.2004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15507543 }} </ref>
| |
| *Vitamin D deficiency<ref name="pmid11493580">{{cite journal| author=Lips P| title=Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. | journal=Endocr Rev | year= 2001 | volume= 22 | issue= 4 | pages= 477-501 | pmid=11493580 | doi=10.1210/edrv.22.4.0437 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11493580 }} </ref>
| |
|
| |
| ===Less common causes===
| |
| *Severe calcium deficiency<ref name="pmid16512945">{{cite journal| author=Mehrotra M, Gupta SK, Kumar K, Awasthi PK, Dubey M, Pandey CM et al.| title=Calcium deficiency-induced secondary hyperparathyroidism and osteopenia are rapidly reversible with calcium supplementation in growing rabbit pups. | journal=Br J Nutr | year= 2006 | volume= 95 | issue= 3 | pages= 582-90 | pmid=16512945 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16512945 }} </ref>
| |
| *Gastric bypass surgery, particularly roux-en-Y gastric bypass (RYGBP)<ref name="pmid16633006">{{cite journal |vauthors=Johnson JM, Maher JW, DeMaria EJ, Downs RW, Wolfe LG, Kellum JM |title=The long-term effects of gastric bypass on vitamin D metabolism |journal=Ann. Surg. |volume=243 |issue=5 |pages=701–4; discussion 704–5 |year=2006 |pmid=16633006 |pmc=1570540 |doi=10.1097/01.sla.0000216773.47825.c1 |url=}}</ref>
| |
| *Malabsorption syndrome<ref name="pmid19836494">{{cite journal |vauthors=Pitt SC, Sippel RS, Chen H |title=Secondary and tertiary hyperparathyroidism, state of the art surgical management |journal=Surg. Clin. North Am. |volume=89 |issue=5 |pages=1227–39 |year=2009 |pmid=19836494 |pmc=2905047 |doi=10.1016/j.suc.2009.06.011 |url=}}</ref>
| |
|
| |
| ==Causes of tertiary hyperparathyroidism==
| |
| Causes of tertiary hyperparathyroidism are as follows:
| |
| ===Common causes===
| |
| *Chronic renal failure (leading to parathyroid hyperplasia)
| |
| *Renal transplant patients<ref name="pmid9780988">{{cite journal |vauthors=Kilgo MS, Pirsch JD, Warner TF, Starling JR |title=Tertiary hyperparathyroidism after renal transplantation: surgical strategy |journal=Surgery |volume=124 |issue=4 |pages=677–83; discussion 683–4 |year=1998 |pmid=9780988 |doi=10.1067/msy.1998.91483 |url=}}</ref>
| |
|
| |
| ===Less common cause===
| |
| *Long standing celiac disease<ref name="pmid17148709">{{cite journal |vauthors=Maida MJ, Praveen E, Crimmins SR, Swift GL |title=Coeliac disease and primary hyperparathyroidism: an association? |journal=Postgrad Med J |volume=82 |issue=974 |pages=833–5 |year=2006 |pmid=17148709 |pmc=2653933 |doi=10.1136/pgmj.2006.045500 |url=}}</ref>
| |
|
| |
|
| |
| =Pathogenesis=
| |
| ==Associated conditions==
| |
| *Hypercalcemia
| |
| *Chronic renal failure
| |
| *Osteitis fibrous cystica
| |
| *Osteoporosis
| |
| *Osteomalacia
| |
| *Osteoarthritis
| |
| *Brown tumor
| |
| *Multiple endocrine neoplasia type 1, type 2A, and type 4
| |
| *Familial isolated hyperparathyroidism
| |
| *Neonatal severe hyperparathyroidism
| |
| *Familial hypocalciuric hypercalcemia
| |
| *Hyperparathyroid-jaw tumor syndrome
| |
| *Pancreatitis<ref name="pmid22874807">{{cite journal |vauthors=Bai HX, Giefer M, Patel M, Orabi AI, Husain SZ |title=The association of primary hyperparathyroidism with pancreatitis |journal=J. Clin. Gastroenterol. |volume=46 |issue=8 |pages=656–61 |year=2012 |pmid=22874807 |pmc=4428665 |doi=10.1097/MCG.0b013e31825c446c |url=}}</ref>
| |
|
| |
| =Natural history, Prognosis and Complications=
| |
| ==Natural history==
| |
| *Primary hyperparathyroidism usually develops in the fifth decade of life, in post-menopausal women and starts as asymptomatic hypercalcemia in presence of increased parathyroid hormone.
| |
| *If left untreated, some of patients with primary hyperparathyroidism may commonly develop marked hypercalcemia, marked hypercalciuria, cortical bone demineralization and nephrolithiasis.<ref name="pmid12412783">{{cite journal |vauthors=Peacock M |title=Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum |journal=J. Bone Miner. Res. |volume=17 Suppl 2 |issue= |pages=N87–94 |year=2002 |pmid=12412783 |doi= |url=}}</ref><ref name="pmid2763869">{{cite journal |vauthors=Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV |title=Skeletal disease in primary hyperparathyroidism |journal=J. Bone Miner. Res. |volume=4 |issue=3 |pages=283–91 |year=1989 |pmid=2763869 |doi=10.1002/jbmr.5650040302 |url=}}</ref>
| |
|
| |
| *Secondary hyperparathyroidism arise in the early course of chronic renal failure. As renal failure progress, secondary hyperparathyroidism becomes more notable.<ref name="pmid21897756">{{cite journal |vauthors=Nikodimopoulou M, Liakos S |title=Secondary hyperparathyroidism and target organs in chronic kidney disease |journal=Hippokratia |volume=15 |issue=Suppl 1 |pages=33–8 |year=2011 |pmid=21897756 |pmc=3139677 |doi= |url=}}</ref>
| |
| *Secondary hyperparathyroidism leads to vascular calcification due to elevated calcium and phosphorus levels. This is strongly associated with increase in morbidity and mortality.<ref name="pmid21454719">{{cite journal |vauthors=Cunningham J, Locatelli F, Rodriguez M |title=Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options |journal=Clin J Am Soc Nephrol |volume=6 |issue=4 |pages=913–21 |year=2011 |pmid=21454719 |doi=10.2215/CJN.06040710 |url=http://cjasn.asnjournals.org/content/6/4/913.full}}</ref>
| |
| *If left untreated, secondary hyperparathyroidism carries an increased risk of vascular calcification with increasing age and duration of dialysis in patients.
| |
|
| |
| *Tertiary hyperparathyroidism usually develops in post renal transplant patients.<ref name="pmid12714225">{{cite journal |vauthors=Jevtic V |title=Imaging of renal osteodystrophy |journal=Eur J Radiol |volume=46 |issue=2 |pages=85–95 |year=2003 |pmid=12714225 |doi= 10.1016/S0720-048X(03)00072-X|url=http://www.sciencedirect.com/science/article/pii/S0720048X0300072X?via%3Dihub}}</ref>
| |
| *If left untreated, tertiary hyperparathyroidism in post renal transplant patients may carry the risk of amyloid deposition, calciphylaxis, destructive or erosive spondyloarthropathy, osteonecrosis, and musculoskeletal infections.
| |
|
| |
| ==Complications==
| |
| ===Primary hyperparathyroidism===
| |
| Majority of complications of primary hyperparathyroidism are due to hypercalcemia. Common complications of primary hyperparathyroidism include:
| |
| *Bone related complication:<ref name="pmid25166047">{{cite journal |vauthors=Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, Machado VC, Bilezikian JP |title=Bone disease in primary hyperparathyroidism |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=5 |pages=553–61 |year=2014 |pmid=25166047 |pmc=4315357 |doi= |url=}}</ref><ref name="pmid9801732">{{cite journal |vauthors=Mazzuoli GF, D'Erasmo E, Pisani D |title=Primary hyperparathyroidism and osteoporosis |journal=Aging (Milano) |volume=10 |issue=3 |pages=225–31 |year=1998 |pmid=9801732 |doi= |url=}}</ref>
| |
| **Brown tumor
| |
| **Osteitis fibrous cystica
| |
| **Osteoporosis
| |
| *Cardiac complications:<ref name="pmid8989242">{{cite journal |vauthors=Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B |title=Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=1 |pages=106–12 |year=1997 |pmid=8989242 |doi=10.1210/jcem.82.1.3666 |url=}}</ref>
| |
| **Aortic and mitral valve calcification
| |
| **Calcific deposits in the myocardium
| |
| **Left ventricular hypertrophy
| |
| *Endocrine complications:<ref name="pmid22874807">{{cite journal |vauthors=Bai HX, Giefer M, Patel M, Orabi AI, Husain SZ |title=The association of primary hyperparathyroidism with pancreatitis |journal=J. Clin. Gastroenterol. |volume=46 |issue=8 |pages=656–61 |year=2012 |pmid=22874807 |pmc=4428665 |doi=10.1097/MCG.0b013e31825c446c |url=}}</ref>
| |
| **Pancreatitis
| |
| *Gastrointestinal complications:<ref name="pmid3878002">{{cite journal |vauthors=Corlew DS, Bryda SL, Bradley EL, DiGirolamo M |title=Observations on the course of untreated primary hyperparathyroidism |journal=Surgery |volume=98 |issue=6 |pages=1064–71 |year=1985 |pmid=3878002 |doi= |url=}}</ref>
| |
| **Peptic ulcer disease
| |
| *Metabolic complications:<ref name="pmid3812520">{{cite journal |vauthors=Fitzpatrick LA, Bilezikian JP |title=Acute primary hyperparathyroidism |journal=Am. J. Med. |volume=82 |issue=2 |pages=275–82 |year=1987 |pmid=3812520 |doi= |url=}}</ref><ref name="pmid25447624">{{cite journal |vauthors=Ahmad S, Kuraganti G, Steenkamp D |title=Hypercalcemic crisis: a clinical review |journal=Am. J. Med. |volume=128 |issue=3 |pages=239–45 |year=2015 |pmid=25447624 |doi=10.1016/j.amjmed.2014.09.030 |url=}}</ref><ref name="pmid3878002">{{cite journal |vauthors=Corlew DS, Bryda SL, Bradley EL, DiGirolamo M |title=Observations on the course of untreated primary hyperparathyroidism |journal=Surgery |volume=98 |issue=6 |pages=1064–71 |year=1985 |pmid=3878002 |doi= |url=}}</ref><ref name="pmid11493580">{{cite journal| author=Lips P| title=Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. | journal=Endocr Rev | year= 2001 | volume= 22 | issue= 4 | pages= 477-501 | pmid=11493580 | doi=10.1210/edrv.22.4.0437 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11493580 }} </ref>
| |
| **Hypercalcemic crisis
| |
| **Osteomalacia
| |
| *Neuromuscular complications:
| |
| **Neuropathic muscle disease
| |
| *Pregnancy related complications:<ref name="pmid17569990">{{cite journal |vauthors=Poomthavorn P, Ongphiphadhanakul B, Mahachoklertwattana P |title=Transient neonatal hypoparathyroidism in two siblings unmasking maternal normocalcemic hyperparathyroidism |journal=Eur. J. Pediatr. |volume=167 |issue=4 |pages=431–4 |year=2008 |pmid=17569990 |doi=10.1007/s00431-007-0528-6 |url=}}</ref>
| |
| **Neonatal hypoparathyroidism
| |
| *Psychiatric complications:<ref name="pmid19336505">{{cite journal |vauthors=Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, Cosman F, Silverberg SJ |title=Neuropsychological features in primary hyperparathyroidism: a prospective study |journal=J. Clin. Endocrinol. Metab. |volume=94 |issue=6 |pages=1951–8 |year=2009 |pmid=19336505 |pmc=2690425 |doi=10.1210/jc.2008-2574 |url=}}</ref><ref name="pmid21917870">{{cite journal |vauthors=Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA |title=Depression in primary hyperparathyroidism: prevalence and benefit of surgery |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=11 |pages=E1737–45 |year=2011 |pmid=21917870 |doi=10.1210/jc.2011-1486 |url=}}</ref><ref name="pmid2608590">{{cite journal |vauthors=McAllion SJ, Paterson CR |title=Psychiatric morbidity in primary hyperparathyroidism |journal=Postgrad Med J |volume=65 |issue=767 |pages=628–31 |year=1989 |pmid=2608590 |pmc=2429194 |doi= |url=}}</ref>
| |
| **Anxiety
| |
| **Cognitive dysfunction including verbal memory and nonverbal abstraction
| |
| **Depression
| |
| **Irritability
| |
| **Lack of concentration
| |
| **Sleep disturbances
| |
| *Renal complications:<ref name="pmid12412783">{{cite journal |vauthors=Peacock M |title=Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum |journal=J. Bone Miner. Res. |volume=17 Suppl 2 |issue= |pages=N87–94 |year=2002 |pmid=12412783 |doi= |url=}}</ref><ref name="pmid22470864">{{cite journal |vauthors=Lila AR, Sarathi V, Jagtap V, Bandgar T, Menon PS, Shah NS |title=Renal manifestations of primary hyperparathyroidism |journal=Indian J Endocrinol Metab |volume=16 |issue=2 |pages=258–62 |year=2012 |pmid=22470864 |pmc=3313745 |doi=10.4103/2230-8210.93745 |url=}}</ref><ref name="pmid19808852">{{cite journal |vauthors=Tassone F, Gianotti L, Emmolo I, Ghio M, Borretta G |title=Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism |journal=J. Clin. Endocrinol. Metab. |volume=94 |issue=11 |pages=4458–61 |year=2009 |pmid=19808852 |doi=10.1210/jc.2009-0587 |url=}}</ref>
| |
| **Hypercalciuria
| |
| **Nephrolithiasis
| |
| **Nephrocalcinosis
| |
| **Renal insufficiency (impairement of GFR)
| |
| *Rheumatologic complications:<ref name="pmid20305774">{{cite journal |vauthors=Michael JW, Schlüter-Brust KU, Eysel P |title=The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee |journal=Dtsch Arztebl Int |volume=107 |issue=9 |pages=152–62 |year=2010 |pmid=20305774 |pmc=2841860 |doi=10.3238/arztebl.2010.0152 |url=}}</ref><ref>{{cite book | last = Hochberg | first = Marc | title = Rheumatology|chapter=204. Primary hyperparathyroidism: rheumatologic manifestations and bone disease |page=1668| publisher = Mosby/Elsevier | location = Philadelphia, PA | year = 2015 | isbn = 9780323091381}}</ref><ref name="pmid11890884">{{cite journal |vauthors=Rubin MR, Silverberg SJ |title=Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy |journal=Curr Rheumatol Rep |volume=4 |issue=2 |pages=179–85 |year=2002 |pmid=11890884 |doi= |url=}}</ref>
| |
| **Gout
| |
| **Osteoarthritis
| |
| **Pseudogout
| |
|
| |
| ===Secondary hyperparathyroidism===
| |
| Complications of secondary hyperparathyroidism includes:
| |
| *Cardiovascular complications:<ref name="pmid11256521">{{cite journal |vauthors=Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Włodarczyk Z, Manitius J |title=Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients |journal=Ren Fail |volume=23 |issue=1 |pages=115–26 |year=2001 |pmid=11256521 |doi= |url=}}</ref>
| |
| **Impaired left ventricular diastolic function
| |
| **Left ventricular hypertrophy
| |
| *Hematologic complication:<ref name="pmid6118720">{{cite journal |vauthors=Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E, Mecca G, de Gaetano G |title=Parathyroid hormone inhibits human platelet function |journal=Lancet |volume=2 |issue=8259 |pages=1321–3 |year=1981 |pmid=6118720 |doi= 10.1016/S0140-6736(81)91343-X |url=http://www.sciencedirect.com/science/article/pii/S014067368191343X?via%3Dihub}}</ref>
| |
| **Platlet function inhibition
| |
| *Metabolic complicattions:<ref name="pmid22258399">{{cite journal |vauthors=Saab G, Whaley-Connell A, Bombeck A, Kurella Tamura M, Li S, Chen SC, McFarlane SI, Sowers JR, Norris K, Bakris GL, McCullough PA |title=The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease |journal=Cardiorenal Med |volume=1 |issue=2 |pages=123–130 |year=2011 |pmid=22258399 |pmc=3101512 |doi=10.1159/000327149 |url=}}</ref><ref name="HjelmesæthHofsø2009">{{cite journal|last1=Hjelmesæth|first1=Jøran|last2=Hofsø|first2=Dag|last3=Aasheim|first3=Erlend T|last4=Jenssen|first4=Trond|last5=Moan|first5=Johan|last6=Hager|first6=Helle|last7=Røislien|first7=Jo|last8=Bollerslev|first8=Jens|title=Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study|journal=Cardiovascular Diabetology|volume=8|issue=1|year=2009|pages=7|issn=1475-2840|doi=10.1186/1475-2840-8-7}}</ref>
| |
|
| |
| **Metabolic syndrome
| |
| *Musculoskeletal complications:<ref name="pmid9158318">{{cite journal |vauthors=Spaulding CM, Young G |title=Osteitis fibrosa cystica and chronic renal failure |journal=J Am Podiatr Med Assoc |volume=87 |issue=5 |pages=238–40 |year=1997 |pmid=9158318 |doi=10.7547/87507315-87-5-238 |url=http://www.japmaonline.org/doi/10.7547/87507315-87-5-238?url_ver=Z39.88-2003&rfr_dat=cr_pub%3Dpubmed&rfr_id=ori:rid:crossref.org&code=pmas-site}}</ref><ref name="pmid328228">{{cite journal |vauthors=Eastwood JB |title=Renal osteodystrophy--a radiological review |journal=CRC Crit Rev Diagn Imaging |volume=9 |issue=1 |pages=77–104 |year=1977 |pmid=328228 |doi= |url=}}</ref><ref name="pmid10633462">{{cite journal |vauthors=Adams JE |title=Renal bone disease: radiological investigation |journal=Kidney Int. Suppl. |volume=73 |issue= |pages=S38–41 |year=1999 |pmid=10633462 |doi= |url=}}</ref>
| |
| **Renal Osteodystrophy
| |
| ***Brown cysts
| |
| ***Osteitis fibrosa cystica
| |
| ***Osteoporosis
| |
| ***Osteosclerosis
| |
| *Neurologic complications:<ref name="pmid6892917">{{cite journal |vauthors=Goldstein DA, Feinstein EI, Chui LA, Pattabhiraman R, Massry SG |title=The relationship between the abnormalities in electroencephalogram and blood levels of parathyroid hormone in dialysis patients |journal=J. Clin. Endocrinol. Metab. |volume=51 |issue=1 |pages=130–4 |year=1980 |pmid=6892917 |doi=10.1210/jcem-51-1-130 |url=}}</ref><ref name="pmid205786">{{cite journal |vauthors=Avram MM, Feinfeld DA, Huatuco AH |title=Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia |journal=N. Engl. J. Med. |volume=298 |issue=18 |pages=1000–3 |year=1978 |pmid=205786 |doi=10.1056/NEJM197805042981805 |url=}}</ref>
| |
| **Electroencephalogram abnormalities
| |
| **Uremic neuropathy
| |
| *Neuromuscular complications:<ref name="pmid47234">{{cite journal |vauthors=Mallette LE, Patten BM, Engel WK |title=Neuromuscular disease in secondary hyperparathyroidism |journal=Ann. Intern. Med. |volume=82 |issue=4 |pages=474–83 |year=1975 |pmid=47234 |doi= |url=}}</ref>
| |
| **Neuropathic muscle disease
| |
| *System non-specific complications:<ref name="pmid9531176">{{cite journal |vauthors=Block GA, Hulbert-Shearon TE, Levin NW, Port FK |title=Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study |journal=Am. J. Kidney Dis. |volume=31 |issue=4 |pages=607–17 |year=1998 |pmid=9531176 |doi= |url=}}</ref>
| |
| **Metastatic calcifications
| |
|
| |
| ===Tertiary hyperparathyroidism===
| |
| Complications of tertiary hyperparathyroidism post renal transplantation includes:<ref name="pmid12714225">{{cite journal |vauthors=Jevtic V |title=Imaging of renal osteodystrophy |journal=Eur J Radiol |volume=46 |issue=2 |pages=85–95 |year=2003 |pmid=12714225 |doi= 10.1016/S0720-048X(03)00072-X|url=http://www.sciencedirect.com/science/article/pii/S0720048X0300072X?via%3Dihub}}</ref>
| |
| *Metabolic complications:<ref name="pmid9451734">{{cite journal |vauthors=Barbur MA, Kurjak M, Becker K |title=[Systematic calciphylaxis in chronic renal failure: fulminant course after kidney transplantation] |language=German |journal=Pathologe |volume=18 |issue=6 |pages=453–8 |year=1997 |pmid=9451734 |doi= |url=}}</ref>
| |
| **Calciphylaxis
| |
| *Musculoskeletal complications:
| |
| **Musculoskeletal infections
| |
| **Osteonecrosis
| |
| *Neuromuscular complications:<ref name="pmid646555">{{cite journal |vauthors=Gerhardt RE, Zeitlin EL |title=Neuromuscular disease in tertiary hyperparathyroidism |journal=Arch. Intern. Med. |volume=138 |issue=6 |pages=1013–5 |year=1978 |pmid=646555 |doi= |url=}}</ref>
| |
| **Neuropathic muscle disease
| |
| *Renal complications:<ref name="pmid11590898">{{cite journal |vauthors=Kim H, Cheigh JS, Ham HW |title=Urinary stones following renal transplantation |journal=Korean J. Intern. Med. |volume=16 |issue=2 |pages=118–22 |year=2001 |pmid=11590898 |pmc=4531707 |doi= |url=}}</ref>
| |
| **Nephrolithiasis
| |
| *Rheumatologic complications:<ref name="pmid2712794">{{cite journal |vauthors=Adler JS, Cameron DC |title=Erosive spondylo-arthropathy and tertiary hyperparathyroidism |journal=Australas Radiol |volume=33 |issue=1 |pages=90–2 |year=1989 |pmid=2712794 |doi= |url=}}</ref>
| |
| **Destructive or erosive spondyloarthropathy
| |
| *System non-specific complications:
| |
| **Amyloid deposition
| |
| **Metastatic calcifications
| |
|
| |
| ==Prognosis==
| |
| *Prognosis of primary hyperparathyroidism is generally excellent after parathyroidectomy.
| |
| *The complications of primary hyperparathyroidism resolves after the treatment.
| |
| *Untreated complication of primary hyperparathyroidism may be fatal.<ref name="pmid3878002">{{cite journal |vauthors=Corlew DS, Bryda SL, Bradley EL, DiGirolamo M |title=Observations on the course of untreated primary hyperparathyroidism |journal=Surgery |volume=98 |issue=6 |pages=1064–71 |year=1985 |pmid=3878002 |doi= |url=}}</ref>
| |
|
| |
| *Effective treatment can reduce morbidity and mortality associated with uncontrolled secondary hyperparathyroidism.<ref name="pmid21454719">{{cite journal |vauthors=Cunningham J, Locatelli F, Rodriguez M |title=Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options |journal=Clin J Am Soc Nephrol |volume=6 |issue=4 |pages=913–21 |year=2011 |pmid=21454719 |doi=10.2215/CJN.06040710 |url=}}</ref>
| |
| *Hyperphosphatemia and metastatic calcification results due elevated product of serum calcium and serum phosphorus. Both conditions are present in patients with secondary hyperparathyroidism in presence of end stage renal disease. This leads to a significant increase in morbidity and mortality. Aggressive control of hyperphosphatemia may improve prognosis<ref name="pmid9531176">{{cite journal |vauthors=Block GA, Hulbert-Shearon TE, Levin NW, Port FK |title=Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study |journal=Am. J. Kidney Dis. |volume=31 |issue=4 |pages=607–17 |year=1998 |pmid=9531176 |doi= |url=}}</ref>.
| |
|
| |
| *Prognosis of tertiary hyperparathyroidism is generally good after resection of abnormal hyperplastic gland.<ref name="pmid11981213">{{cite journal |vauthors=Nichol PF, Starling JR, Mack E, Klovning JJ, Becker BN, Chen H |title=Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma |journal=Ann. Surg. |volume=235 |issue=5 |pages=673–8; discussion 678–80 |year=2002 |pmid=11981213 |pmc=1422493 |doi= |url=}}</ref>
| |
|
| |
|
| |
| =ECG=
| |
| There are no CT scan findings associated with hyperparathyroidism. However, a CT scan may be helpful in the diagnosis of cardiac complications of hyperparathyroidism.
| |
| Findings on ECG are due to hypercalcemia and includes:<ref name="pmid8201301">{{cite journal |vauthors=Lind L, Ljunghall S |title=Serum calcium and the ECG in patients with primary hyperparathyroidism |journal=J Electrocardiol |volume=27 |issue=2 |pages=99–103 |year=1994 |pmid=8201301 |doi= |url=}}</ref>
| |
| *ST segment - ST segment is short in patients with hyperparathyroidism when compared to normocalcemic patients. This represents a decrease in systolic interval.
| |
| *QRS complex - QRS complex has an increased amplitudein patients with hyperparathyroidism when compared to normocalcemic patients. This represents an increase in ventricular muscle mass.
| |
| *T wave - T wave is prolonged in patients with hyperparathyroidism when compared to normocalcemic patients.
| |
|
| |
| =X-ray=
| |
| {|
| |
| |-
| |
| | | | | |
| Finding in primary hyperparathyroidism includes:<ref name="pmid24614783">{{cite journal |vauthors=Lachungpa T, Sarawagi R, Chakkalakkoombil SV, Jayamohan AE |title=Imaging features of primary hyperparathyroidism |journal=BMJ Case Rep |volume=2014 |issue= |pages= |year=2014 |pmid=24614783 |pmc=3962932 |doi=10.1136/bcr-2013-203521 |url=}}</ref>
| |
| *Subperiosteal bone resorption
| |
| **Classically affects the radial aspects of the proximal and middle phalanges of the 2nd and 3rd fingers
| |
| **Medial aspect of tibia, femur, humerus
| |
| **Phalyngeal tuft erosion (acro-osteolysis)
| |
| **Lamina dura around teeth (floating teeth)
| |
| *Endoosteal bone resorption
| |
| **Widening of medullary cavity
| |
| **Thinning of the inner cortex
| |
| *Subchondral resorption
| |
| **Lateral end of the clavicles
| |
| **Symphysis pubis
| |
| **Sacroiliac joints
| |
| *Subligamentous resorption
| |
| **Ischial tuberosity
| |
| **Humeral tuberosity
| |
| **Trochanters
| |
| **Inferior surface of calcaneus
| |
| **Inferior margin of lateral clavicle
| |
| *Intracortical resorption: cigar/oval-shaped or tunnel-shaped radiolucency in the cortex
| |
| *Osteopaenia
| |
| *Brown tumours
| |
| *Salt and pepper sign in the skull (pepper pot skull)
| |
| *Chondrocalcinosis
| |
|
| |
| X-ray is the preferred imaging for diagnosis of secondary hyperparathyroidism as majority of findings are radiological. <ref name="pmid7785573">{{cite journal |vauthors=Tigges S, Nance EP, Carpenter WA, Erb R |title=Renal osteodystrophy: imaging findings that mimic those of other diseases |journal=AJR Am J Roentgenol |volume=165 |issue=1 |pages=143–8 |year=1995 |pmid=7785573 |doi=10.2214/ajr.165.1.7785573 |url=http://www.ajronline.org/doi/pdf/10.2214/ajr.165.1.7785573}}</ref>
| |
| Findings in secondary and tertiary hyperparathyroidism are often associated with the osteosclerosis of renal osteodystrophy, and the osteomalacia of vitamin D deficiency:
| |
| *Subperiosteal bone resorption
| |
| **Radial aspect of middle phalanges of index and long fingers are involved.
| |
| *Subchondral resorption
| |
| **Hands, hips, shoulders, patellofemoral and sacroiliac joints are involved.
| |
| **Hands are involves in the ulnar side.
| |
| **Distal interphalangeal and metacarpophalangeal joints are involved.
| |
| **Subchondral resorption is very severe. It may lead to bony collapse.
| |
| *Subligamentous resorption
| |
| **Retrocalcaneal bursa and insertion of planter aponeurosis may be involved.
| |
| *Severe osteopenia, may be complicated by pathologic fractures
| |
| *Osteosclerosis, e.g. rugger-jersey spine
| |
| *Brown tumor
| |
| *Amyloid deposition
| |
| **May be manifested as lytic bone lesion on radiograph
| |
| *Soft tissue and vascular calcification
| |
| *Superior and inferior rib notching
| |
| *Osteonecrosis may be often observed in patients in whom steroid is administered for prevention of renal transplant rejection.
| |
| |- | | |- |
| | | | | |
| [[image:Subperiosteal bone resorption.gif|thumb|600px|Subperiosteal bone resorption - [https://radiopaedia.org/articles/subperiosteal-bone-resorption Source:Radiopedia]]]
| |
| | | | | |
| [[image:Brown tumor.gif|thumb|600px|Brown tumors - [https://radiopaedia.org/cases/renal-osteodystrophy-and-brown-tumours-1 Source:Case courtesy of A.Prof Frank Gaillard, Radiopedia]]]
| |
| |-
| |
| | | | | |
| [[image:Salt-and-pepper-sign-skull compared to normal skull.png|thumb|600px|Normal skull compared to Salt & pepper appearance of skull - [https://radiopaedia.org/cases/21127 Source:Radiopedia]]]
| |
| | | | | |
| [[image:Acro-osteolytis.gif|thumb|600px|Acro-osteolytis, terminal tufts erosion - [https://radiopaedia.org/cases/9738 Source:Case courtesy of Dr Andrew Dixon, Radiopedia]]]
| |
| |} | | |} |
| =CT scan=
| |
|
| |
| =MRI=
| |
|
| |
| =Ultrasound=
| |
|
| |
| =Sestamibi scintigraphy=
| |
| *Technetium-99m-methoxyisobutylisonitrile (99mTc-sestamibi or MIBI) scintigraphy is the most popular investigation for preoperative localization of hyper-functioning parathyroid glands.<ref name="pmid16150247">{{cite journal| author=Palestro CJ, Tomas MB, Tronco GG| title=Radionuclide imaging of the parathyroid glands. | journal=Semin Nucl Med | year= 2005 | volume= 35 | issue= 4 | pages= 266-76 | pmid=16150247 | doi=10.1053/j.semnuclmed.2005.06.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150247 }} </ref>
| |
| *Most of the sestamibi is retained in mitochondria of thyroid and abnormal parathyroid tissue and is a function of mitochondrial activity.<ref name="pmid11742331">{{cite journal| author=Hetrakul N, Civelek AC, Stagg CA, Udelsman R| title=In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. | journal=Surgery | year= 2001 | volume= 130 | issue= 6 | pages= 1011-8 | pmid=11742331 | doi=10.1067/msy.2001.118371 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11742331 }} </ref>
| |
| *The basis of this "single-isotope, double-phase technique" is that sestamibi washes out of the thyroid more rapidly than from abnormal parathyroid tissue.<ref name="pmid1328564">{{cite journal| author=Taillefer R, Boucher Y, Potvin C, Lambert R| title=Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study) | journal=J Nucl Med | year= 1992 | volume= 33 | issue= 10 | pages= 1801-7 | pmid=1328564 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1328564 }} </ref>
| |
| *Multiple planar images are obtained, typically one shortly after injection of 99mTc-sestamibi and another after two hours to identify the foci of retained sestamibi showing hyper-functioning parathyroid tissue.
| |
| *As all parathyroid lesions does not retain sestamibi nor all thyroid tissue washes out quickly, subtraction imaging may be beneficial.<ref name="pmid8288719">{{cite journal| author=Thulé P, Thakore K, Vansant J, McGarity W, Weber C, Phillips LS| title=Preoperative localization of parathyroid tissue with technetium-99m sestamibi 123I subtraction scanning. | journal=J Clin Endocrinol Metab | year= 1994 | volume= 78 | issue= 1 | pages= 77-82 | pmid=8288719 | doi=10.1210/jcem.78.1.8288719 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8288719 }} </ref><ref name="pmid25722888">{{cite journal| author=Ryhänen EM, Schildt J, Heiskanen I, Väisänen M, Ahonen A, Löyttyniemi E et al.| title=(99m)Technetium Sestamibi-(123)Iodine Scintigraphy Is More Accurate Than (99m)Technetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism. | journal=Int J Mol Imaging | year= 2015 | volume= 2015 | issue= | pages= 391625 | pmid=25722888 | doi=10.1155/2015/391625 | pmc=4333274 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25722888 }} </ref>
| |
| *Presence of solid thyroid nodule is the most common cause of false positive results. Other causes of false positive results may include thyroid carcinoma, lymphoma, and lymphadenopathy.
| |
| *The sensitivity of sestamibi scintigraphy can be increased by using it concomitantly with neck ultrasound and/or SPECT. <ref name="pmid18794320">{{cite journal| author=Eslamy HK, Ziessman HA| title=Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. | journal=Radiographics | year= 2008 | volume= 28 | issue= 5 | pages= 1461-76 | pmid=18794320 | doi=10.1148/rg.285075055 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18794320 }} </ref><ref name="pmid12153604">{{cite journal| author=Haber RS, Kim CK, Inabnet WB| title=Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. | journal=Clin Endocrinol (Oxf) | year= 2002 | volume= 57 | issue= 2 | pages= 241-9 | pmid=12153604 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12153604 }} </ref>
| |
| *The sensitivity of sestamibi scintigraphy is 80% - 90%.<ref name="pmid8678959">{{cite journal |vauthors=Chapuis Y, Fulla Y, Bonnichon P, Tarla E, Abboud B, Pitre J, Richard B |title=Values of ultrasonography, sestamibi scintigraphy, and intraoperative measurement of 1-84 PTH for unilateral neck exploration of primary hyperparathyroidism |journal=World J Surg |volume=20 |issue=7 |pages=835–9; discussion 839–40 |year=1996 |pmid=8678959 |doi= |url=}}</ref><ref name="pmid17685957">{{cite journal |vauthors=Prasannan S, Davies G, Bochner M, Kollias J, Malycha P |title=Minimally invasive parathyroidectomy using surgeon-performed ultrasound and sestamibi |journal=ANZ J Surg |volume=77 |issue=9 |pages=774–7 |year=2007 |pmid=17685957 |doi=10.1111/j.1445-2197.2007.04227.x |url=}}</ref><ref name="pmid20625763">{{cite journal |vauthors=Gómez-Ramírez J, Sancho-Insenser JJ, Pereira JA, Jimeno J, Munné A, Sitges-Serra A |title=Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism |journal=Langenbecks Arch Surg |volume=395 |issue=7 |pages=929–33 |year=2010 |pmid=20625763 |doi=10.1007/s00423-010-0680-8 |url=}}</ref>
| |
|
| |
| =SPECT=
| |
| *Single positron emission computed tomography may be used along with Tc-99m sestamibi scintigraphy for preoperative evaluation of hyper-functioning parathyroid gland.<ref name="pmid8917173">{{cite journal| author=Billotey C, Sarfati E, Aurengo A, Duet M, Mündler O, Toubert ME et al.| title=Advantages of SPECT in technetium-99m-sestamibi parathyroid scintigraphy. | journal=J Nucl Med | year= 1996 | volume= 37 | issue= 11 | pages= 1773-8 | pmid=8917173 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8917173 }} </ref><ref name="pmid11854692">{{cite journal| author=Civelek AC, Ozalp E, Donovan P, Udelsman R| title=Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. | journal=Surgery | year= 2002 | volume= 131 | issue= 2 | pages= 149-57 | pmid=11854692 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11854692 }} </ref>
| |
| *Sestamibi-SPECT is also called pinhone-SPECT (P-SPECT). P-SPECT uses cone beam collimator in contrast to parallel-hole collimator used in SPECT. cone bean collimator possess more suitable geometric properties leading to high spatial resolution.<ref name="pmid8306288">{{cite journal| author=Strand SE, Ivanovic M, Erlandsson K, Franceschi D, Button T, Sjögren K et al.| title=Small animal imaging with pinhole single-photon emission computed tomography. | journal=Cancer | year= 1994 | volume= 73 | issue= 3 Suppl | pages= 981-4 | pmid=8306288 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8306288 }} </ref><ref name="pmid15551591">{{cite journal| author=Jaszczak RJ, Li J, Wang H, Zalutsky MR, Coleman RE| title=Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. | journal=Phys Med Biol | year= 1994 | volume= 39 | issue= 3 | pages= 425-37 | pmid=15551591 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15551591 }} </ref>
| |
| *Using SPECT with sestamibi scintigraphy improves detection and localization of hyper-functioning parathyroid gland.<ref name="pmid15078713">{{cite journal| author=Schachter PP, Issa N, Shimonov M, Czerniak A, Lorberboym M| title=Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy. | journal=Arch Surg | year= 2004 | volume= 139 | issue= 4 | pages= 433-7 | pmid=15078713 | doi=10.1001/archsurg.139.4.433 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15078713 }} </ref><ref name="pmid8816526">{{cite journal| author=Perez-Monte JE, Brown ML, Shah AN, Ranger NT, Watson CG, Carty SE et al.| title=Parathyroid adenomas: accurate detection and localization with Tc-99m sestamibi SPECT. | journal=Radiology | year= 1996 | volume= 201 | issue= 1 | pages= 85-91 | pmid=8816526 | doi=10.1148/radiology.201.1.8816526 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8816526 }} </ref>
| |
| *SPECT provides more precise result of sestamibi scitigraphy allowing surgeon to choose best route for surgical intervention.
| |
| *P-SPECT may detect glands not visible on planer images leading to increased sensitivity. It is very useful in case of uncertain result from conventional sestamibi scitigraphy.<ref name="pmid14734671">{{cite journal| author=Spanu A, Falchi A, Manca A, Marongiu P, Cossu A, Pisu N et al.| title=The usefulness of neck pinhole SPECT as a complementary tool to planar scintigraphy in primary and secondary hyperparathyroidism. | journal=J Nucl Med | year= 2004 | volume= 45 | issue= 1 | pages= 40-8 | pmid=14734671 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14734671 }} </ref><ref name="pmid17960377">{{cite journal |vauthors=Carlier T, Oudoux A, Mirallié E, Seret A, Daumy I, Leux C, Bodet-Milin C, Kraeber-Bodéré F, Ansquer C |title=99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography |journal=Eur. J. Nucl. Med. Mol. Imaging |volume=35 |issue=3 |pages=637–43 |year=2008 |pmid=17960377 |pmc=2964350 |doi=10.1007/s00259-007-0625-9 |url=}}</ref>
| |
| *P-SPECT also enables accurate interpretation sestamibi uptake in upper mediastinum leading to a higher specificity.
| |
| *In difficult cases, P-SPECT may also be adjuncted with subtraction Tc-99m sestamibi and I-123 scintigraphy or positron emission tomography.<ref name="pmid10336191">{{cite journal| author=Nguyen BD| title=Parathyroid imaging with Tc-99m sestamibi planar and SPECT scintigraphy. | journal=Radiographics | year= 1999 | volume= 19 | issue= 3 | pages= 601-14; discussion 615-6 | pmid=10336191 | doi=10.1148/radiographics.19.3.g99ma10601 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10336191 }} </ref>
| |
| *P-SPECT is approximately 84% sensitive, 91% specific with positive predictive value of around 91% and negative predictive value of around 84%.<ref name="pmid19578871">{{cite journal |vauthors=Lindqvist V, Jacobsson H, Chandanos E, Bäckdahl M, Kjellman M, Wallin G |title=Preoperative 99Tc(m)-sestamibi scintigraphy with SPECT localizes most pathologic parathyroid glands |journal=Langenbecks Arch Surg |volume=394 |issue=5 |pages=811–5 |year=2009 |pmid=19578871 |doi=10.1007/s00423-009-0536-2 |url=}}</ref>
| |
| *Fusion images of CT-MIBI-SPECT is superior to CT or MIBI-SPECT alone in preoperative localization of hyper-functioning parathyroid gland.<ref name="pmid19705144">{{cite journal| author=Wimmer G, Profanter C, Kovacs P, Sieb M, Gabriel M, Putzer D et al.| title=CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. | journal=Langenbecks Arch Surg | year= 2010 | volume= 395 | issue= 1 | pages= 73-80 | pmid=19705144 | doi=10.1007/s00423-009-0545-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19705144 }} </ref>
| |
|
| |
|
| =PET=
| |
| *11C-methionine PET along with CT scan (MET-PET/CT) may be used for preoperative localization of hyper-functioning gland.<ref name="pmid18781582">{{cite journal| author=Tang BN, Moreno-Reyes R, Blocklet D, Corvilain B, Cappello M, Delpierre I et al.| title=Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. | journal=Contrast Media Mol Imaging | year= 2008 | volume= 3 | issue= 4 | pages= 157-63 | pmid=18781582 | doi=10.1002/cmmi.243 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18781582 }} </ref><ref name="pmid23478517">{{cite journal| author=Weber T, Maier-Funk C, Ohlhauser D, Hillenbrand A, Cammerer G, Barth TF et al.| title=Accurate preoperative localization of parathyroid adenomas with C-11 methionine PET/CT. | journal=Ann Surg | year= 2013 | volume= 257 | issue= 6 | pages= 1124-8 | pmid=23478517 | doi=10.1097/SLA.0b013e318289b345 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23478517 }} </ref>
| |
| *MET-PET/CT may be used as an complimentary imaging modality for localizing hyper-functioning parathyroid glands in patients with negative Tc-99m sestamibi scintigraphy/SPECT results.<ref name="pmid25029418">{{cite journal| author=Traub-Weidinger T, Mayerhoefer ME, Koperek O, Mitterhauser M, Duan H, Karanikas G et al.| title=11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 11 | pages= 4199-205 | pmid=25029418 | doi=10.1210/jc.2014-1267 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25029418 }} </ref>
| |
| ==References== | | ==References== |
| | {{reflist|2}} |